Literature DB >> 10804540

Bacterial vaginosis in pregnancy.

J A McGregor1, J I French.   

Abstract

Bacterial vaginosis is a clinical condition caused by replacement of the normal hydrogen peroxide producing Lactobacillus sp. in the vagina with high concentrations of characteristic sets of aerobic and anaerobic bacteria. Bacterial vaginosis is the most prevalent cause of vaginal discharge or malodor, although 50 percent of women who meet the criteria for this condition are asymptomatic. Bacterial vaginosis is reported in 10 to 41 percent of women, and new evidence has shown association with maternal and fetal morbidity. Studies have shown that spontaneous abortion, preterm labor, premature birth, preterm premature rupture of the membranes, amniotic fluid infection, postpartum endometritis, and postcesarean wound infections are increased because of infection with bacterial vaginosis during pregnancy. Clinical trials demonstrated important reductions in many of these adverse events with appropriate screening and antimicrobial treatment protocols. New low-cost, diagnostic, point-of-care screening tools are available for rapid screening of patients, affording the physician the opportunity to potentially make a dramatic clinical and cost impact in preventing preterm birth and the costly sequelae of prematurity. Practicing physicians need to be aware of current guidelines for screening and treating pregnant patients for bacterial vaginosis. The authors recommend that all pregnant women be screened and treated with the Centers for Disease Control and Prevention (CDC-P) recommended oral regimens early in pregnancy. Each treated women should be evaluated for "test of cure" 1 month after treatment. Mothers likely to benefit from "screen and treat" approaches include 1) those with the highest concentrations of genital anaerobes and mycoplasmas, 2) women with prior preterm birth or who have low body mass (BMI < 19.8 kg/m2), 3) those with evidence of endometritis before pregnancy, and 4) those who are treated with oral agents effective for both presumed intrauterine mycoplasmas and other bacterial vaginosis flora (i.e., oral clindamycin or erythromycin and metronidazole).

Entities:  

Mesh:

Year:  2000        PMID: 10804540     DOI: 10.1097/00006254-200005001-00001

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  37 in total

1.  DNA hybridization test: rapid diagnostic tool for excluding bacterial vaginosis in pregnant women with symptoms suggestive of infection.

Authors:  Armin Witt; Ljubomir Petricevic; Ulrike Kaufmann; Hubertus Gregor; Herbert Kiss
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

2.  Candida Vulvovaginitis in Pregnancy.

Authors:  Jinping Xu; Jack D Sobel
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

3.  Vaginal symptoms and bacterial vaginosis (BV): how useful is self-report? Development of a screening tool for predicting BV status.

Authors:  D B Nelson; S Bellamy; A Odibo; I Nachamkin; R B Ness; L Allen-Taylor
Journal:  Epidemiol Infect       Date:  2007-02-05       Impact factor: 2.451

Review 4.  Preterm birth due to maternal infection: Causative pathogens and modes of prevention.

Authors:  M V Pararas; C L Skevaki; D A Kafetzis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

5.  The vaginal microbiome in health and disease.

Authors:  Bryan A White; Douglas J Creedon; Karen E Nelson; Brenda A Wilson
Journal:  Trends Endocrinol Metab       Date:  2011-07-13       Impact factor: 12.015

6.  Characteristics and pregnancy outcomes of pregnant women asymptomatic for bacterial vaginosis.

Authors:  Deborah B Nelson; Scarlett Bellamy; Bonnie A Clothier; George A Macones; Irving Nachamkin; Althea Ruffin; Lynne Allen-Taylor; Frank K Friedenberg
Journal:  Matern Child Health J       Date:  2007-06-02

7.  Racial differences in cervical cytokine concentrations between pregnant women with and without bacterial vaginosis.

Authors:  Kelli K Ryckman; Scott M Williams; Marijane A Krohn; Hyagriv N Simhan
Journal:  J Reprod Immunol       Date:  2008-03-11       Impact factor: 4.054

8.  Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women.

Authors:  Sabina Cauci; Silvia Driussi; Davide De Santo; Paola Penacchioni; Teresa Iannicelli; Paolo Lanzafame; Francesco De Seta; Franco Quadrifoglio; Domenico de Aloysio; Secondo Guaschino
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

9.  Lactobacillus rhamnosus GR-1 stimulates colony-stimulating factor 3 (granulocyte) (CSF3) output in placental trophoblast cells in a fetal sex-dependent manner.

Authors:  Maryam Yeganegi; Chiashan G Leung; Andrew Martins; Sung O Kim; Gregor Reid; John R G Challis; Alan D Bocking
Journal:  Biol Reprod       Date:  2010-09-01       Impact factor: 4.285

10.  Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery.

Authors:  Herbert Kiss; Ljubomir Petricevic; Peter Husslein
Journal:  BMJ       Date:  2004-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.